# A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma

> **NCT01020292** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 31 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Nelfinavir

## Key facts

- **NCT ID:** NCT01020292
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01020292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01020292, "A Trial of the Protease Inhibitor Nelfinavir and Concurrent Radiation and Temozolomide in Patients With WHO Grade IV Glioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01020292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*